Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Neogen is set to report Q3 results on Apr 9 with consensus EPS of $0.05 vs $0.10 year-ago (‑50% YoY) and revenue of $204.62M vs $220.98M year-ago (≈‑7.4% YoY). The company announced the sale of its Genomics business to Zoetis on March 2. Shares were modestly higher, up 1.6% to $9.56 on Monday. Given the expected YoY declines in EPS and revenue, the print could move the stock within the typical 1–3% range for earnings releases.

Analysis

Neogen's recent portfolio reshaping creates a classic short-term growth headwind but a medium-term margin opportunity: shedding lower-margin or non-core revenue can depress top-line metrics this quarter while improving EBITDA margins 200–400bps over 6–18 months if SG&A and R&D are reallocated efficiently. The recurring consumables/diagnostics footprint that remains tends to produce sticky, high-margin cash flow; optimizing channel economics (direct vs distributor) and contract manufacturing cadence will determine whether that margin pickup is realized or eroded by transitional costs.

For the buyer, scale effects and cross-sell into an installed veterinary/food-safety base are the primary value levers, but integration risk (customer attrition, one-time purchase accounting, and working capital timing) can create a 1–3 quarter earnings drag that markets punish harshly. Key near-term catalysts that could reverse negative sentiment are explicit capital-allocation moves (≥5% buyback or targeted bolt-ons) within 90 days, or a 2–3 quarter cadence of margin improvement that converts to free cash flow and debt flexibility within 12 months.

Contrarian read: the market is pricing a permanent revenue downgrade rather than a temporary reset; that underweights the optionality from redeploying proceeds into high-ROIC buybacks or niche M&A. If management executes even modest buybacks (5–8% of float) and preserves the consumables attach rate, a 12–24 month re-rating of 25–40% versus peers is plausible, while downside remains event-driven around the next two quarterly prints and any integration headlines from the buyer.

Key Decisions for Investors

• Event-driven asymmetric option: If NEOG gaps down ≥8% post-earnings or trades below $8.50, initiate a 3–6 month call spread (buy NEOG 6-mo $10 call / sell $15 call) sized to 1–2% portfolio risk. Max loss = premium; target 2.5x return if execution and margin rhetoric convert to visible FCF in 6–12 months.
• Relative-value pair: Go long ZTS (2–4% portfolio) and short NEOG (equal $ notional) for 6–12 months to capture likely acquirer integration tailwinds and seller discounting. Use 8–12% stop on the short leg and trim longs at 6–8% absolute gains; target 5–10% absolute relative outperformance.
• Event-trigger equity play: Allocate up to 3% portfolio long NEOG only if management announces a buyback ≥5% of market cap within 90 days — hold 12–24 months, target 25–40% upside, stop-loss 20% from entry.
• Volatility/timing rule: Avoid selling/collecting premium across the upcoming print. If IV collapses post-earnings and fundamentals are intact, consider selling 1–2 month call spreads against a small long position to monetize premium with defined downside.